Research, development, and production to support clinical trials for HIV vaccines.
Active Awarded Last action
- Contract number
- 75N91022F00006
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $14,347,608
Award facts
- Contract value 60% obligated
-
- $14,347,608.00 Current, with exercised options
- $23,855,636.00 Potential, with all options
- Completion date 75% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $758,088 | |
| Other Administrative Action | $95,420 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $340,426 | |
| Exercise an Option | $9,802,681 | |
| Original award | $3,350,993 |
About this award
This is a $23,855,636.00 Cost Plus Fixed Fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for research, development, and production to support clinical trials for HIV vaccines. This work is being performed at Leidos Biomedical Research facilities in Frederick, Maryland. The contract does not have a set-aside designation. Leidos Biomedical Research Inc. is a Federally Funded Research and Development Center (FFRDC) contractor for the National Cancer Institute (NCI) and has supported various biomedical research and development efforts across disease areas including HIV/AIDS, COVID-19, and gene therapy. The parent company, Leidos Holdings, Inc., has acted as a subcontractor on past federal contracts, providing services, engineering support, and other goods and services.
Quick answers
Who was awarded contract 75N91022F00006?
75N91022F00006 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on April 12, 2022.
How much is contract 75N91022F00006 worth?
The government has obligated $14,347,608 on 75N91022F00006. Its potential value, with all options, is $23,855,636.
Which agency awarded contract 75N91022F00006?
National Cancer Institute (National Institutes of Health) awarded 75N91022F00006, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91022F00006 an order under another contract?
Yes. 75N91022F00006 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91022F00006 competed?
The extent of competition for 75N91022F00006 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award